Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA To Expand TAP Pilot Program

Executive Summary

The US Food and Drug Administration is set to expand a pilot program aimed at speeding up the development of innovative medical devices. The agency will begin enrolling more devices in the Total Product Lifecycle Advisory Program, which the agency rolled out in January.

You may also be interested in...

‘Banner Year’ For FDA’s Device Center Includes Record Number Of Novel Authorizations

A new annual report argues that last year was both transformative and historic for the US FDA’s Center for Devices and Radiological Health. The center authorized the highest number of novel medical devices in history while turning the corner on the pandemic.

Stakeholders: Get Ready To Submit TAP Program Feedback In FY 2025

CDRH officials updated stakeholders about the CDRH’s strategic plan for promoting health equity and the TAP Pilot program at a recent MDIC meeting.

More But Slower Medtech Approvals

If the pace is maintained in the second half of the year, 2023 could see the most US device approvals in a decade.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts